Physician profile
James Quertermous
NPI 1184919508
$1,692.28
in general payments reported to CMS, 2019-2025
22 companies · $37.95 in 2025
The $37.95 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $232 · 2021: $67.61 · 2022: $330 · 2023: $243 · 2024: $170 · 2025: $37.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $214.65 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $189.58 | 2021-2024 | Libtayo |
| Janssen Biotech, INC. | $176.24 | 2019-2022 | |
| Leo Pharma INC. | $161.23 | 2019-2025 | Adbry |
| Amgen INC. | $110.74 | 2019-2022 | |
| Organogenesis INC. | $109.36 | 2023 | Puraply |
| Sun Pharmaceutical Industries INC. | $95.12 | 2019-2024 | Winlevi |
| Ucb, INC. | $86.61 | 2019-2020 | |
| Genzyme Corporation | $85.58 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $75.28 | 2019-2024 | |
| Incyte Corporation | $62.83 | 2023-2024 | Opzelura |
| Galderma Laboratories, L.P. | $59.53 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.17 | 2019-2023 | Arazlo |
| Lilly USA, LLC | $52.80 | 2019-2023 | Olumiant, Taltz |
| Celgene Corporation | $35.18 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $29.48 | 2019 | |
| Biofrontera INC. | $18.34 | 2022 | |
| Encore Dermatology INC. | $16.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.63 | 2019 | |
| Pfizer INC. | $15.05 | 2019 | |
| Dermavant Sciences, INC. | $14.07 | 2023 | Vtama |
| Dusa Pharmaceuticals, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Quertermous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.